Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults - PubMed (original) (raw)

Multicenter Study

. 2007 Dec;92(12):1695-8.

doi: 10.3324/haematol.11709.

Affiliations

Free article

Multicenter Study

Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults

Drew Provan et al. Haematologica. 2007 Dec.

Free article

Abstract

We conducted a retrospective analysis of 11 consecutive patients with various autoimmune cytopenias who failed to respond to conventional treatments and received a fixed-dose regimen of rituximab (100 mg weekly for 4 consecutive weeks). Sustained complete responses were achieved in 4 out of 7 patients with idiopathic thrombocytopenic purpura and in 1 patient with autoimmune pancytopenia. A partial response was observed in 1 patient with autoimmune hemolytic anemia. The immunotherapy had no effect in 1 patient with pure red cell aplasia or in 1 patient with autoimmune neutropenia. No infusion-related or delayed toxicities attributable to rituximab were experienced by any of the patients.

PubMed Disclaimer

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources